Chronic Thromboembolic Pulmonary Hypertension – Drugs In Development, 2024
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Chronic Thromboembolic Pulmonary Hypertension – Drugs In Development, 2024 report and make more profitable business decisions.
Chronic thromboembolic pulmonary hypertension (CTEPH) also called as Chronic pulmonary embolism, is a pulmonary vascular disease caused by chronic block of the major lung arteries. It is the major cause of chronic PH leading to right heart failure and death.
The Chronic Thromboembolic Pulmonary Hypertension drugs in development market research report provide comprehensive information on the therapeutics under development for Chronic Thromboembolic Pulmonary Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Thromboembolic Pulmonary Hypertension and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
Quick View – Chronic Thromboembolic Pulmonary Hypertension | Key Targets |
|
|
Key Mechanisms of Action |
|
||
Key Routes of Administration |
|
||
Key Molecule Types |
|
||
Major Companies |
|
Scope
- Therapeutics in Development: Covering 6 molecules, with 6 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Chronic Thromboembolic Pulmonary Hypertension therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Chronic Thromboembolic Pulmonary Hypertension pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Chronic Thromboembolic Pulmonary Hypertension treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Bayer AGDaiichi Sankyo Co Ltd
Guangdong East Sunshine Pharmaceutical Co Ltd
Johnson & Johnson
Pharmosa Biopharm Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Chronic Thromboembolic Pulmonary Hypertension reports![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)
![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)
![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)